Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data.

Mudi MisgavTami Brutman-BarazaniIvan BudnikEinat AvishaiJonathan SchapiroDalia BashariAssaf A BargAaron LubetskyTami Livnat Gili Kenet

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)

Emicizumab prophylaxis for HA patients older than 50 years including those with cardiovascular risk factors was well tolerated. As lower emicizumab and TG levels were observed among bleeding patients, we suggest that monitoring laboratory assays could be of value within this age group.

Keyphrases

cardiovascular risk factors
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
metabolic syndrome
cardiovascular disease
type diabetes
physical activity
atrial fibrillation
electronic health record
artificial intelligence
big data